Bailard’s MediciNova MNOV Stock Holding History

Bailard’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,507	Closed	-$44K	–	720
2022 Q2	$44K	Sell	17,507 -10,715	-38%	-$28K	﹤0.01%	674
2022 Q1	$75K	Buy	+28,222	New	+$69.1K	﹤0.01%	700

Other funds holding MNOV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bailard's MNOV Position: Q3 2022 in Review

Bailard sold out of MediciNova (MNOV) in Q3 2022, closing a stake of 17,507 shares — an estimated $44K sold.

Bailard first reported a position in MNOV in Q1 2022 and held it in 2 quarters. The position peaked at $75K in Q1 2022. 35 funds tracked by Wall St. Rank hold MNOV as of Q3 2022.

Bailard reported no remaining MediciNova position as of Q3 2022 after selling out during the quarter.
Bailard sold 17,507 MediciNova shares in Q3 2022, an estimated $44K.
Bailard first reported a position in MediciNova in Q1 2022 and held it in 2 quarters.
Bailard's MediciNova position peaked at $75K in Q1 2022.
35 funds tracked by Wall St. Rank held MediciNova as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.